Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galera Therapeutics Inc.

www.galeratx.com

Latest From Galera Therapeutics Inc.

Finance Watch: As US IPO Market Gets More Challenging, Two Companies Opt Out

Public Company Edition: Five biopharma firms went public in the US in recent weeks, but Inhibrx withdrew its IPO and Monopar postponed its offering. Also, Tot Biopharm launched an IPO in Hong Kong, while Epizyme sold royalties and issued debt to raise up to $270m.

Financing Business Strategies

Finance Watch: Phathom IPO Meets Pricing Goal; Cabaletta, TFF Offerings Go Low

Public Company Edition: Phathom went public in the US within proposed pricing terms, but Cabaletta’s IPO went to market below a proposed range, while TFF launched in line with earlier plans. Also, Principia’s FOPO raises $210m and Trillium restructures.

Financing Business Strategies

Venture Funding Deals: Atreca Raises $125m To Advance Solid Tumor Candidate

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August and September.

Deals Financing

Deal Watch: Astellas/Cytokinetics Extend Partnership, Make Progress On SMA Candidate

The two firms hope improvement in the six-minute walk test might be accepted by the US FDA as registrational endpoint for reldesemtiv in spinal muscular atrophy. Blackstone acquires Clarus, while Merck licenses TriNKETs from Dragonfly.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dental & Oral Products
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Galera Therapeutics Inc.
  • Senior Management
  • J. Mel Sorensen, MD, Pres. & CEO
    Chris Degnan, CFO
    Robert A Beardsley, PhD, COO
    Dennis P Riley, PhD, CSO
    Jon T Holmlund, MD, CMO
    Arthur Fratamico, CBO
  • Contact Info
  • Galera Therapeutics Inc.
    Phone: (610) 725-1500
    2 West Liberty Blvd.
    Ste. 110
    Malvern, PA 19355
    USA
UsernamePublicRestriction

Register